Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 26 | 34 | +8 |
| Shares | 3.57M | 2.94M | −630.2K (−17.7%) |
| Value | $4.87M | $6.15M | +$1.28M (+26.2%) |
New holders (11)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Connor, Clark & Lunn Investment Management Ltd. | 158,703 | $333.3K | 0.00% |
| Marshall Wace, LLP | 150,358 | $315.8K | 0.00% |
| Millennium Management LLC | 86,698 | $182.0K | 0.00% |
| XTX Topco Ltd | 34,064 | $71.5K | 0.01% |
| Two Sigma Securities, LLC | 20,760 | $43.6K | 0.00% |
| Sculptor Capital LP | 19,100 | $40.1K | 0.00% |
| Aptus Capital Advisors, LLC | 16,010 | $33.6K | 0.00% |
| Lido Advisors, LLC | 15,554 | $32.7K | 0.00% |
| HRT Financial LP | 10,309 | $21.0K | 0.00% |
| Truvestments Capital LLC | 3,880 | $8.15K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,602 | $3.00K | 0.00% |
Sold out (3)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Highbridge Capital Management LLC | 2,413,487 | $3.31M |
| Smith, Salley & Associates | 12,048 | $16.5K |
| Ten Capital Wealth Advisors, LLC | 1,000 | $1.37K |